[1] |
Felson DT,Klareskog L.The genetics of rheumatoid arthritis:new insights and implications[J]. JAMA,2015,313(16):1623-1624.
|
[2] |
Wasilenko WJ,Palad AJ,Somers KD,et al.Effects of the calcium influx inhibitor carboxyamido-triazole on the proliferation and invasiveness of human prostate tumor cell lines[J]. Int J Cancer,1996,68(2):259-264.
|
[3] |
Moody TW,Chiles J,Moody E,et al.CAI inhibits the growth of small cell lung cancer cells[J]. Lung Cancer,2003,39(3):279-288.
|
[4] |
郭磊,李娟,叶华,等. 抗肿瘤药物羧胺三唑的抗炎镇痛作用[J]. 中国医学科学院学报,2009,31(3):315-321.
|
[5] |
朱蕾,李娟,武丹威,等. 羧胺三唑对角叉菜胶诱导急性炎症的抗炎作用[J]. 中国临床药理学与治疗学,2013,18(6):601-606.
|
[6] |
Ahmed AS,Li J,Ahmed M,et al.Attenuation of pain and inflammation in adjuvant-induced arthritis by the proteasome inhibitor MG132[J]. Arthritis Rheum,2010,62(7):2160-2169.
|
[7] |
Zhu L,Wei W,Zheng YQ,et al.Effects and mechanisms of total glucosides of paeony on joint damage in rat collagen-induced arthritis[J]. Inflamm Res,2005,54(5):211-220.
|
[8] |
Hegen M,Keith JC Jr,Collins M,et al.Utility of animal models for identification of potential therapeutics for rheumatoid arthritis[J]. Ann Rheum Dis,2008,67(11):1505-1515.
|
[9] |
Gavril BI,Ciofu C,Stoica V,et al.The efficiency of biologic therapy in a group of patients with rheumatoid arthritis[J]. J Med Life,2015,8(1):79-84.
|
[10] |
Wang D,Li Y,Liu Y,et al.The use of biologic therapies in the treatment of rheumatoid arthritis[J]. Curr Pharm Biotechnol,2014,15(6):542-548.
|
[11] |
Dayer JM,Choy E.Therapeutic targets in rheumatoid arthritis:the interleukin-6 receptor[J]. Rheumatology (Oxford),2010,49(1):15-24.
|
[12] |
García-Hernández MH,González-Amaro R,Portales-Pérez DP.Specific therapy to regulate inflammation in rheumatoid arthritis:molecular aspects[J]. Immunotherapy,2014,6(5): 623-636.
|
[13] |
Figg WD,Cole KA,Reed E,et al.Pharmacokinetics of orally administered carboxyamido-triazole,an inhibitor of calcium-mediated signal transduction[J]. Clin Cancer Res,1995,1(8):797-803.
|
[14] |
Stadler WM,Rosner G,Small E,et al.Successful implementation of the randomized discontinuation trial design:an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma-CALGB 69901[J]. J Clin Oncol,2005,23(16):3726-3732.
|